IBNtxA

IBNtxA is a chemical compound that is used in scientific research. It is a selective agonist for the melanocortin 4 receptor, which is a G protein-coupled receptor that is expressed in the central nervous system. The melanocortin 4 receptor is involved in regulating food intake and energy homeostasis, and it is a target for the development of drugs for the treatment of obesity and related conditions.

Chemical structure and properties

IBNtxA is a peptide that is derived from the natural ligand for the melanocortin 4 receptor, alpha-MSH. It has a molecular weight of approximately 1000 daltons, and it is composed of nine amino acids. The sequence of amino acids in IBNtxA is Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2.

Pharmacology

IBNtxA is a potent and selective agonist for the melanocortin 4 receptor. It has a half-life of approximately 2 hours in the bloodstream, and it is metabolized by proteases in the liver and kidneys. IBNtxA has been shown to reduce food intake and increase energy expenditure in animal models, and it is being investigated for its potential use in the treatment of obesity and related conditions.

Clinical significance

The melanocortin 4 receptor is a major regulator of food intake and energy homeostasis, and mutations in the gene that encodes this receptor are associated with severe obesity in humans. Drugs that activate the melanocortin 4 receptor, such as IBNtxA, have the potential to reduce food intake and increase energy expenditure, and they could be used to treat obesity and related conditions. However, the development of such drugs is challenging due to the complexity of the melanocortin system and the potential for side effects.

See also

• Melanocortin 4 receptor
• Obesity
• G protein-coupled receptor
• Agonist

IBNtxA Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski